MedTrace Logo

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

NCT07153666 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2026-01-02

No results posted yet for this study

Summary

Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.

Conditions

  • Vitiligo

Interventions

DRUG

Ruxolitinib 1.5% Cream BID

ruxolitinib twice per day

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Jinzhu Guo, MD · Peking University Third Hospital

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07153666 on ClinicalTrials.gov